- Home
- NSPR vs KZIA Comparison
NSPR vs KZIA Comparison
Compare NSPR & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NSPR | KZIA |
|---|---|---|
| Founded | 2005 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.4M | 74.1M |
| IPO Year | 2009 | 2002 |
Fundamental Metrics
Financial Performance| Metric | NSPR | KZIA |
|---|---|---|
| Price | $1.83 | $8.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $4.00 | ★ $17.67 |
| AVG Volume (30 Days) | 16.8K | ★ 187.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.32 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,310,000.00 | N/A |
| Revenue This Year | $22.91 | N/A |
| Revenue Next Year | $72.30 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.51 | $0.64 |
| 52 Week High | $3.48 | $17.40 |
Technical Indicators
Market Signals| Indicator | NSPR | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 59.33 | 67.61 |
| Support Level | $1.62 | $7.54 |
| Resistance Level | $2.51 | $8.94 |
| Average True Range (ATR) | 0.12 | 0.74 |
| MACD | 0.02 | 0.36 |
| Stochastic Oscillator | 81.98 | 92.78 |
Price Performance
Historical ComparisonAbout NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.